High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients

Journal of Surgical Oncology

Volumn 102, Issue 5, 2010, Pages 503-508

  Langer, Rupert ^a   Ott, Katja ^b   Feith, Marcus ^a   Lordick, Florian ^c   Specht, Katja ^a   Becker, Karen ^a   Hofler, Heinz ^a,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c KLINIKUM BRAUNSCHWEIG   (Germany)

^d National Research Center for Environment and Health   (Germany)

Author keywords

Chemotherapy; MRP 1; Oesophageal adenocarcinoma; Thymidylate synthetase

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; FOLINIC ACID; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC AGENT; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN; TUMOR PROTEIN;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CONTINUOUS INFUSION; CORRELATION ANALYSIS; DRUG TREATMENT FAILURE; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BIOPSY; ADENOCARCINOMA; ADJUVANT THERAPY; ESOPHAGEAL NEOPLASMS; METABOLISM; MIDDLE AGED; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; P-GLYCOPROTEIN; SURVIVAL ANALYSIS; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 77957349990     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21641     Document Type: Article

References (33)

1. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
2. Siewert JR, Lordick F, Ott K, et al.: Induction chemotherapy in Barrett cancer: Influence on surgical risk and outcome. Ann Surg 2007;246:624-628; discussion 628-631.
3. Chang F, Deere H, Mahadeva U, et al.: Histopathologic examination and reporting of esophageal carcinomas following preoperative neoadjuvant therapy: Practical guidelines and current issues. Am J Clin Pathol 2008;129:252-262. (Pubitemid 352029316)
4. Gebski V, Burmeister B, Smithers BM, et al.: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet Oncol 2007;8:226-234. (Pubitemid 46291702)
5. Rizk NP, Venkatraman E, Bains MS, et al.: American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol 2007;25:507-512. (Pubitemid 350002956)
6. Lordick F, Ott K, Krause BJ, et al.: PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: The MUNICON phase II trial. Lancet Oncol 2007;8:797-805. (Pubitemid 47308659)
7. Luthra MG, Ajani JA, Izzo J, et al.: Decreased expression of gene cluster at chromosome 1q21 defines molecular subgroups of chemoradiotherapy response in esophageal cancers. Clin Cancer Res 2007;13:912-919. (Pubitemid 46340367)
8. Luthra R, Wu TT, Luthra MG, et al.: Gene expression profiling of localized esophageal carcinomas: Association with pathologic response to preoperative chemoradiation. J Clin Oncol 2006;24:259-267. (Pubitemid 46628468)
9. Langer R, Ott K, Specht K, et al.: Protein expression profiling in esophageal adenocarcinoma patients reveals association of heat shock protein 27 expression and chemotherapy response. Clin Cancer Res 2008;14:8279-8787.
10. Harpole DH, Jr., Moore MB, Herndon JE II, et al.: The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2001;7:562-569.
11. Langer R, Specht K, Becker K, et al.: Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-7469. (Pubitemid 41507707)
12. Wang XP, Qiu FR, Liu GZ, et al.: Correlation between clinicopathology and expression of heat shock protein 70 and glucose-regulated protein 94 in human colonic adenocarcinoma. World J Gastroenterol 2005;11:1056-1059. (Pubitemid 40347764)
13. Sato E, Olson SH, Ahn J, et al.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543. (Pubitemid 43011261)
14. Izzo JG, Correa AM, Wu TT, et al.: Pretherapy nuclear factor-kappaB status, chemoradiation resistance, and metastatic progression in esophageal carcinoma. Mol Cancer Ther 2006;5:2844-2850.
15. Izzo JG, Malhotra U, Wu TT, et al.: Association of activated transcription factor nuclear factor kappab with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006;24:748-754. (Pubitemid 46622041)
16. Fernebro E, Dictor M, Bendahl PO, et al.: Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 2002;126:702-705. (Pubitemid 34602572)
17. Bader FG, Lordick F, Fink U, et al.: Paclitaxel in the neoadjuvant treatment for adeno carcinoma of the distal esophagus (AEG I). A comparison of two phase II trials with long-term follow-up. Onkologie 2008;31:366-372.
18. Becker K, Mueller JD, Schulmacher C, et al.: Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-1530. (Pubitemid 37151509)
19. Specht K, Richter T, Muller U, et al.: Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-429. (Pubitemid 32158605)
20. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). J Clin Oncol (Meeting Abstracts) 2005;23:4001.
21. Qiu LX, Tang QY, Bai JL, et al.: Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies. Int J Cancer 2008;123:2384-2389.
22. Popat S, Matakidou A, Houlston RS: Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22:529-536. (Pubitemid 41079782)
23. Warnecke-Eberz U, Metzger R, Miyazono F, et al.: High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004;10:3794-3799. (Pubitemid 38697614)
24. Theisen J, Danenberg K, Ott K, et al.: Predictors of response and survival for neoadjuvant treated patients with esophageal adenocarcinoma. Dis Esophagus 2008;21:601-606.
25. Napieralski R, Ott K, Kremer M, et al.: Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 2005;11:3025-3031. (Pubitemid 40525208)
26. Abolhoda A, Wilson AE, Ross H, et al.: Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. Clin Cancer Res 1999;5:3352-3356.
27. Leonard GD, Fojo T, Bates SE: The role of ABC transporters in clinical practice. Oncologist 2003;8:411-424. (Pubitemid 37238869)
28. Vilmar A, Sorensen JB: Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: A review of current literature. Lung Cancer 2009;64:131-139.
29. Roy S, Kenny E, Kennedy S, et al.: MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer. Anticancer Res 2007;27:1325-1330. (Pubitemid 46807278)
30. Langer R, Specht K, Becker K, et al.: Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy- associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. Am J Clin Pathol 2007;128:191-197. (Pubitemid 47262616)
31. Schneider S, Uchida K, Brabender J, et al.: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg 2005;200:336-344. (Pubitemid 40298967)
32. Di Nicolantonio F, Mercer S, Knight L, et al.: Cancer cell adaptation to chemotherapy. BMC Cancer 2005;5:78.
33. Luthra R, Luthra MG, Izzo J, et al.: Biomarkers of response to preoperative chemoradiation in esophageal cancers. Semin Oncol 2006;33:S2-S5.